Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15317876 | 0.81 | EPHX1 (0.41) | EPHX1NAAAHTTCYP19A1CYP2C19 | |
| SCHEMBL6887454 | 0.80 | EPHX1 (0.46) | EPHX1NAAAHTTCYP19A1CYP2C19 | |
| SCHEMBL9694970 | 0.78 | EPHX1 (0.43) | EPHX1NAAAHTTCYP19A1CYP2C19 | |
| SCHEMBL2986206 | 0.78 | EPHX1 (0.47) | EPHX1NAAAHTTCYP19A1CYP2C19 | |
| SCHEMBL2983911 | 0.78 | EPHX1 (0.47) | EPHX1NAAAHTTCYP19A1CYP2C19 | |
| SCHEMBL12306829 | 0.78 | EPHX1 (0.47) | EPHX1NAAAHTTCYP19A1CYP2C19 | |
| SCHEMBL2981153 | 0.78 | EPHX1 (0.47) | EPHX1NAAAHTTCYP19A1CYP2C19 | |
| SCHEMBL2992790 | 0.78 | EPHX1 (0.47) | EPHX1NAAAHTTCYP19A1CYP2C19 | |
| SCHEMBL6272147 | 0.78 | NAAA (0.39) | EPHX1NAAAHTTCYP19A1CYP2C19 | |
| SCHEMBL19669582 | 0.78 | AKT1 (0.38) | EPHX1NAAAHTTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477989-A1 | COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120172598-A1 | COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-07-05 | — | — | US | disclosed |
| WO-2011034215-A1 | COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172598-A1 | COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITY | TAF1, TFPI, TAF1L | EPHX1 3636/4885NAAA 1285/4885HTT 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.